Clover Health Investments Corp (NASDAQ:CLOV)’s traded shares stood at 4.98 million during the last session, with the company’s beta value hitting 1.86. At the close of trading, the stock’s price was $0.79, to imply an increase of 1.58% or $0.01 in intraday trading. The CLOV share’s 52-week high remains $1.63, putting it -106.33% down since that peak but still an impressive 10.13% since price per share fell to its 52-week low of $0.71. The company has a valuation of $391.35M, with an average of 11.27 million shares in intraday trading volume over the past 10 days and average of 9.54 million shares over the past 3 months.
Clover Health Investments Corp (NASDAQ:CLOV) trade information
After registering a 1.58% upside in the last session, Clover Health Investments Corp (CLOV) has traded red over the past five days. The stock hit a weekly high of 0.9098, jumping 1.58% in its intraday price action. The 5-day price performance for the stock is -10.09%, and -11.70% over 30 days. With these gigs, the year-to-date price performance is -16.71%. Short interest in Clover Health Investments Corp (NASDAQ:CLOV) saw shorts transact 47.54 million shares and set a 3.45 days time to cover.
Clover Health Investments Corp (CLOV) estimates and forecasts
Looking at statistics comparing Clover Health Investments Corp share performance against respective industry, we note that the company has outperformed competitors. Clover Health Investments Corp (CLOV) shares are -29.20% down over the last 6 months, with its year-to-date growth rate higher than industry average at 51.22% against 20.00%. Revenue is forecast to grow 53.30% this quarter before jumping 33.30% for the next one. The rating firms project that company’s revenue will shrink -37.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $321.23 million. Meanwhile, for the quarter ending Jun 2024, a total of 3 analyst(s) estimate revenue growth to $321.13 million.Earnings reports from the last fiscal year show that sales brought in $527.77 million and $513.63 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -39.10% before dropping -37.50% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -585.84% for the past 5-year period. While 2024 is set for a 50.14% return in earnings, projections for the next 5 years are at 19.10% annually.
CLOV Dividends
Clover Health Investments Corp has its next earnings report out between May 07 and May 13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Clover Health Investments Corp has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Clover Health Investments Corp (NASDAQ:CLOV)’s Major holders
Clover Health Investments Corp insiders hold 7.39% of total outstanding shares, with institutional holders owning 24.45% of the shares at 26.40% float percentage. In total, 24.45% institutions holds shares in the company, led by Vanguard Group Inc. As of Jun 29, 2023, the company held over 31.43 million shares (or 7.92% of shares), all amounting to roughly $28.2 million.
The next major institution holding the largest number of shares is Renaissance Technologies, LLC with 8.85 million shares, or about 2.23% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $7.94 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund as the top two Mutual Funds with the largest holdings of the Clover Health Investments Corp (CLOV) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 10.28 million shares. This is just over 2.59% of the total shares, with a market valuation of $9.22 million. Data from the same date shows that the other fund manager holds a little less at 9.15 million, or 2.30% of the shares, all valued at about 8.21 million.
